



**The National Leiomyosarcoma Foundation in collaborative partnership with CURE ID launched the Repurposed Drug Initiative for Leiomyosarcoma patients to participate in a patient registry. The treatment registry collects data from patients and their care partners that will be analyzed to see if any existing FDA-approved drugs could be potentially safe and effective treatment options for Leiomyosarcoma (LMS).**

**Drug repurposing refers to the identification of approved drugs for new diseases.** The advantage of repurposing drugs is that these products have already been determined to be safe in humans and here is often a great deal known about their safety profiles from previous research. In addition, the drugs are currently available to patients, and therefore, could be accessible much more rapidly than a drug that is being developed from scratch. Despite the advances in oncology research, cancers are still associated with the most unmet medical needs. Therefore, it is critical that we work together to identify effective treatments through platforms like CURE ID.

This PUBMED article from 2023 on the topic of repurposing drugs entitled: Unlocking hidden potential advancements, approaches, and obstacles in repurposing drugs for cancer therapy offer valuable insight into such an initiative: [Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy - PubMed](#).

More information on the CURE ID for the Sarcoma Project is available here:

<https://cure.ncats.io/pilot-overview/sarcoma>.

Demonstration videos of the site and how to enter your report for Sarcoma are available at:

<https://cure.ncats.io/resources/faqs> under the “Case Report Demonstration Videos” Heading for Rare Cancers (Sarcoma).

Answers to Frequently Asked Questions about CURE ID are available here:

<https://cure.ncats.io/resouces/faqs> under the “Frequently Asked Questions: Headline.

For technical questions or IT support, you may contact: [curesupport@nih.gov](mailto:curesupport@nih.gov).

For questions about the collaboration, please contact [annieachee@aol.com](mailto:annieachee@aol.com) or [heather.stone@fda.hhs.gov](mailto:heather.stone@fda.hhs.gov).